Oct. 19, 2020 05:30 UTC
STRASBOURG, France–(BUSINESS WIRE)– Regulatory Information:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech firm that designs and develops virus-based immunotherapeutics in opposition to most cancers, introduced that detailed outcomes of the info from the Section 1b/2 trial combining TG4001, a HPV16 focused therapeutic vaccine, with avelumab (BAVENCIO®), a human anti-PD-L1 antibody, in HPV16-positive recurrent and/or metastatic malignancies, will likely be offered in a poster presentation on the upcoming digital assembly of the Society for Immunotherapy of Most cancers (SITC) happening November 9-14, 2020.
The principal investigator Professor Christophe Le Tourneau will current outcomes from a pooled evaluation of the Section 1b/2 trial, together with response price, median progression-free survival, in addition to the impression of affected person/illness traits on consequence and immunogenicity.
As a reminder, the evaluation of the trial information demonstrated scientific exercise of the mix routine and confirmed a manageable security profile.
The aim of this exploratory Section 1b/2 trial was to judge the security and efficacy of the mix of TG4001 and an immune checkpoint inhibitor in a heterogeneous group of sufferers with aggressive, recurrent and/or metastatic HPV16-positive most cancers. Scientific exercise was noticed within the general research inhabitants (34 evaluable sufferers with oropharyngeal, anal, cervical, or different HPV16-positive cancers).
As well as, Transgene has recognized affected person traits related to promising scientific exercise on this trial. For greater than 50% of those sufferers, the illness had not progressed at 12 weeks, in comparison with an anticipated median progression-free survival (PFS) of 8 weeks for this inhabitants with present therapy regimens*. Per information offered at ESMO 2019 [1], sturdy responses have been noticed in many of the responder sufferers.
The trial was being performed in collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer.
Concerning the trial
This multi-center, open-label trial is assessing the security and efficacy of this immunotherapy mixture routine (TG4001 + avelumab) in sufferers with HPV16-positive cancers who’ve illness development after no less than one line of systemic therapy for recurrent/metastatic illness (NCT03260023). Prof. Christophe Le Tourneau, M.D., PhD, Head of the Division of Drug Improvement and Innovation (D3i) on the Curie Institute, and a world knowledgeable in drug improvement and head and neck cancers, is the Principal Investigator of the research. The trial is being performed in collaboration with Merck KGaA, Darmstadt, Germany, a number one science and expertise firm, which within the US and Canada operates its biopharmaceutical enterprise as EMD Serono, and Pfizer Inc. (NYSE: PFE).
Sufferers acquired TG4001 on the dose of 5×107 pfu, SC, weekly for six weeks, each 2 weeks as much as six months, and each 12 weeks thereafter, together with avelumab at 10 mg/kg, IV each two weeks, till illness development.
The first endpoint of the Section 2 half is the general response price (ORR, utilizing RECIST 1.1). Secondary endpoints embody progression-free survival, general survival, illness management price and different immunological parameters.
Extra info on the trial is accessible on clinicaltrials.gov.
***
About HPV-Optimistic Cancers
HPV-positive cancers comprise a wide range of malignancies, together with head and neck cancers and anogenital cancers [7]. Squamous cell carcinoma of the pinnacle and neck (SCCHN) is a heterogeneous group of cancers that may have an effect on websites together with the oral cavity, pharynx, and larynx [8]. The incidence of HPV16-related SCCHN has considerably elevated in recent times [8]. HPV16 an infection is related to greater than 85% of oropharynx squamous cell carcinomas [8], i.e. roughly 10,000 sufferers at metastatic stage and receiving a second line of therapy [9]. Different HPV16-positive cancers embody cervical [10], vaginal [11], vulvar [12], anal [13] and penile [14] cancers, i.e. roughly 15,000 cancers at metastatic stage and eligible for a second line of therapy [15].
Present remedies embody chemoradiotherapy, immune checkpoint inhibitors, or surgical resection with radiotherapy. Nevertheless, higher choices are wanted for superior and metastatic HPV+ cancers. It’s thought that this immunotherapy mixed with different immunotherapeutic brokers corresponding to immune checkpoint inhibitors may present a promising potential therapy choice that may tackle this robust medical want [16,17]. With immune checkpoint inhibitors, median general survival stays inferior to 11 months [2-6] and median progression-free survival is between 2 and 4 months [2-6]. On this heterogenous group of malignancies, general response charges are round 10–15% [2-6].
About TG4001
TG4001 is an investigational therapeutic vaccine primarily based on a non-propagative, extremely attenuated Vaccinia vector (MVA), which is engineered to specific HPV16 antigens (E6 & E7) and an adjuvant (IL-2). TG4001 is designed to have a two-pronged antiviral method: to alert the immune system particularly to HPV-16-infected cells which have began to bear precancerous transformation (cells presenting the HPV16 E6 and E7 antigens) and to additional stimulate the infection-clearing exercise of the immune system via interleukin 2 (IL-2). TG4001 has been administered to greater than 300 people, demonstrating good security, important HPV clearance price and promising efficacy outcomes [1; 18]. Its mechanism of motion and good security profile make TG4001 a superb candidate for mixtures with different therapies in HPV-mediated stable tumors.
Avelumab Permitted Indications
Avelumab (BAVENCIO®) is indicated within the US for the upkeep therapy of sufferers with domestically superior or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy. BAVENCIO can also be indicated for the therapy of sufferers with domestically superior or metastatic UC who’ve illness development throughout or following platinum-containing chemotherapy, or have illness development inside 12 months of neoadjuvant or adjuvant therapy with platinum-containing chemotherapy.
Avelumab together with axitinib is permitted within the US for the first-line therapy of sufferers with superior renal cell carcinoma (RCC).
Within the US, the FDA granted accelerated approval for BAVENCIO for the therapy of adults and pediatric sufferers 12 years and older with metastatic Merkel cell carcinoma (MCC). This indication is permitted below accelerated approval primarily based on tumor response price and period of response. Continued approval could also be contingent upon verification and outline of scientific profit in confirmatory trials.
Avelumab Essential Security Data from the US FDA-Permitted Label
The warnings and precautions for avelumab (BAVENCIO®) embody immune-mediated adversarial reactions (corresponding to pneumonitis and hepatitis [including fatal cases], colitis, endocrinopathies, nephritis, and different immune-mediated adversarial reactions as a single agent or together with axitinib [which can be severe and have included fatal cases]), infusion-related reactions, hepatotoxicity together with axitinib, main adversarial cardiovascular occasions (MACE) together with axitinib [which can be severe and have included fatal cases], and embryo-fetal toxicity.
Widespread adversarial reactions (reported in no less than 20% of sufferers) in sufferers handled with BAVENCIO® monotherapy embody fatigue, musculoskeletal ache, diarrhea, nausea, infusion-related response peripheral edema, decreased urge for food, urinary tract an infection and rash. Widespread adversarial reactions (reported in no less than 20% of sufferers) in sufferers receiving BAVENCIO® together with axitinib embody diarrhea, fatigue, hypertension, musculoskeletal ache, nausea, mucositis, palmar-plantar erythrodysesthesia, dysphonia, decreased urge for food, hypothyroidism, rash, hepatotoxicity, cough, dyspnea, stomach ache and headache. Grade 3-4 hematology laboratory worth abnormalities reported in no less than 10% of sufferers with Merkel cell carcinoma handled with BAVENCIO® monotherapy embody lymphopenia; in sufferers receiving BAVENCIO® together with axitinib, grade 3-4 scientific chemistry abnormalities embody blood triglyceride elevated and lipase elevated.
For full US Prescribing Information and Medication Guide for BAVENCIO®, please see http://www.BAVENCIO.com.
References
[1] Le Tourneau et al. “Section Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in sufferers with recurrent/metastatic HPV16 optimistic cancers” 2019 ESMO Annual Meeting, 30 September 2019, Poster presentation
[2] Cohen et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, part 3 research. Lancet. 2019;393:156–67
[3] Ferris et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016;375:1856-1867
[4] Morris et al. Nivolumab for Beforehand Handled Unresectable Metastatic Anal Most cancers (NCI9673): A Multicentre, Single-Arm, Section 2 Examine. Lancet Oncol. 2017;18(4):446-453
[5] Marabelle et al. Pembrolizumab for beforehand handled superior anal squamous cell carcinoma: Pooled outcomes from the KEYNOTE-028 and KEYNOTE-158 research. J Clin Oncol 38: 2020 (suppl; abstr 4020)
[6] Chung et al. Efficacy and Security of Pembrolizumab in Beforehand Handled Superior Cervical Most cancers: Outcomes From the Section II KEYNOTE-158 Examine. J Clin Oncol. 2019;10;37(17):1470-1478
[7] ICO/IARC – HPV Data Heart> Prevention at a glance – accessed July 2020
[8] Kreimer et al., Human Papillomavirus Sorts in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Assessment. Cancer Epidemiol Biomarkers Prev. 2005;14(2):467-75
[9] HPV-positive oropharynx most cancers: Firm estimates primarily based on: Globocan/IARC 2018 Cancer Fact Sheets: oropharynx (C09-10) – accessed July 2020; ICO/IARC – HPV Data Heart 2018 Statistics – accessed July 2020; Kreimer et al., Human Papillomavirus Sorts in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Assessment. Cancer Epidemiol Biomarkers Prev. 2005;14(2):467-75
[10] HPV-positive cervical most cancers: Globocan/IARC 2018 Cancer Fact Sheets: cervix uteri (C53) – accessed July 2020; ICO/IARC – HPV Data Heart 2018 Statistics – accessed July 2020
[11] HPV-positive vaginal most cancers: Globocan/IARC 2018 Cancer Fact Sheets: vagina (C52) – accessed July 2020; ICO/IARC – HPV Data Heart 2018 Statistics – accessed July 2020; Kreimer et al., Human Papillomavirus Sorts in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Assessment. Cancer Epidemiol Biomarkers Prev. 2005;14(2):467-75
[12] HPV-positive vulvar most cancers: Globocan/IARC 2018 Cancer Fact Sheets: vulva (C51) – accessed July 2020; ICO/IARC – HPV Data Heart 2018 Statistics – accessed July 2020; CDC United States Most cancers Statistics: Data Visualizations – accessed July 2020; SEER Most cancers stat info: vulvar cancer – accessed July 2020
[13] HPV-positive anal most cancers: Globocan/IARC 2018 Cancer Fact Sheets: anus (C21) – accessed July 2020; ICO/IARC – HPV Data Heart 2018 Statistics – accessed July 2020; CDC>Most cancers Residence>HPV and Most cancers>Statistics>Charges by Race and Ethnicity>HPV-Associated Anal Cancer Rates by Race and Ethnicity– accessed July 2020; American Most cancers Society: Anal Cancer – accessed July 2020
[14] HPV-positive penile most cancers: Globocan/IARC 2018 Cancer Fact Sheets: penis (C60) – accessed July 2020; ICO/IARC – HPV Data Heart 2018 Statistics – accessed July 2020; CDC>Most cancers Residence>HPV and Most cancers>Statistics>Charges by Race and Ethnicity>HPV-Associated Cancers Rates by Race and Ethnicity – accessed July 2020; Kreimer et al., Human Papillomavirus Sorts in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Assessment. Cancer Epidemiol Biomarkers Prev. 2005;14(2):467-75
[15] Firm estimates primarily based on notes 10, 11, 12, 13, 14
[16] Melero et al. Evolving synergistic mixtures of focused immunotherapies to fight most cancers. Nat Rev Cancer. 2015;15(8): 457-472.
[17] Van der Burg et al. Vaccines for established most cancers: overcoming the challenges posed by immune evasion Nat Rev Cancer. 2016;16(4):219-233
[18] Harper et al. The Efficacy and Security of Tipapkinogen Sovacivec Therapeutic HPV Vaccine in Cervical Intraepithelial Neoplasia Grades 2 and three: Randomized Managed Section II Trial With 2.5 Years of Observe-Up. Gynecologic Oncology. 2019; 153(3):521-529
About Transgene
Transgene (Euronext: TNG) is a publicly traded French biotechnology firm targeted on designing and growing focused immunotherapies for the therapy of most cancers. Transgene’s applications make the most of viral vector expertise with the aim of not directly or straight killing most cancers cells.
The Firm’s clinical-stage applications encompass two therapeutic vaccines (TG4001 for the therapy of HPV-positive cancers, and TG4050, the primary individualized therapeutic vaccine primarily based on the myvac® platform) in addition to two oncolytic viruses (TG6002 for the therapy of stable tumors, and BT-001, the primary oncolytic virus primarily based on the Invir.IO™ platform).
With Transgene’s myvac® platform, therapeutic vaccination enters the sphere of precision medication with a novel immunotherapy that’s absolutely tailor-made to every particular person. The myvac® method permits the technology of a virus-based immunotherapy that encodes patient-specific mutations recognized and chosen by Synthetic Intelligence capabilities offered by its companion NEC.
With its proprietary platform Invir.IO™, Transgene is constructing on its viral vector engineering experience to design a brand new technology of multifunctional oncolytic viruses. Transgene has an ongoing Invir.IO™ collaboration with AstraZeneca.
Extra details about Transgene is accessible at: www.transgene.fr.
Observe us on Twitter: @TransgeneSA
Disclaimer
This press launch incorporates forward-looking statements, that are topic to quite a few dangers and uncertainties, which may trigger precise outcomes to vary materially from these anticipated. The prevalence of any of those dangers may have a major adverse consequence for the Firm’s actions, views, monetary scenario, outcomes, regulatory authorities’ settlement with improvement phases, and improvement. The Firm’s skill to commercialize its merchandise is determined by however will not be restricted to the next elements: optimistic pre-clinical information is probably not predictive of human scientific outcomes, the success of scientific research, the flexibility to acquire financing and/or partnerships for product manufacturing, improvement and commercialization, and advertising and marketing approval by authorities regulatory authorities. For a dialogue of dangers and uncertainties which may trigger the Firm’s precise outcomes, monetary situation, efficiency or achievements to vary from these contained within the forward-looking statements, please confer with the Danger Components (“Facteurs de Risque”) part of the Common Registration Doc, obtainable on the AMF web site (http://www.amf-france.org) or on Transgene’s web site (www.transgene.fr). Ahead-looking statements communicate solely as of the date on which they’re made and Transgene undertakes no obligation to replace these forward-looking statements, even when new info turns into obtainable sooner or later.
* Present therapy regimens, together with immune checkpoint inhibitors, for sufferers with metastatic illness receiving a second (or additional) line of therapy for his or her HPV16 related indications ship very restricted profit. With immune checkpoint inhibitors, general response charges are round 10–15% on this heterogenous group of malignancies, whereas median general survival is lower than 11 months [2-6] and median progression-free survival is round 2 months [2-6].
View supply model on businesswire.com: https://www.businesswire.com/news/home/20201018005012/en/
